• 1
    Ferencz C, Rubin JD, McCarter RJ, Brenner JL, Neill CA, Perry LW, Hepner SI, Downing JW. Congenital heart disease: prevalence at live birth. The Baltimore-Washington infant study. Am J Epidemiol 1985; 121: 3136.
  • 2
    Hoffman JIE. Incidence of congenital heart disease: I—postnatal incidence, Pediatr Cardiol 1995; 16: 103113.
  • 3
    Cuneo BF, Curran LF, Davis N, Elrad H. Trends in prenatal diagnosis of critical cardiac defects in an integrated obstetric and pediatric cardiac imaging center. J Perinatol 2004; 24: 674678.
  • 4
    Bull C. Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK. Lancet 1999; 354: 12421247.
  • 5
    Abu-Harb M, Hey E, Wren C. Death in infancy from unrecognized congenital heart disease. Arch Dis Child 1994; 71: 37.
  • 6
    Nelson NL, Filly RA, Goldstein RB, Callen PW. The AIUM/ACR antepartum obstetrical sonographic guidelines: expectations for detection of anomalies. J Ultrasound Med 1993; 12: 189196.
  • 7
    Simpson LL. Screening for congenital heart disease. Obstet Gynecol Clin North Am 2004; 31: 5159.
  • 8
    Hunter S, Heads A, Wylie J, Robson S. Prenatal diagnosis of congenital heart disease in the northern region of England: benefits of a training programme for obstetric ultrasonographers. Heart 2000; 84: 294298.
  • 9
    Friedman AH, Kleinman CS, Copel JA. Diagnosis of cardiac defects: where we've been, where we are and where we're going. Prenat Diagn 2002; 22: 280284.
  • 10
    Cardiac screening examination of the fetus: guidelines for performing the ‘basic’ and ‘extended basic’ cardiac scan. International Society of Ultrasound in Obstetrics & Gynecology. Ultrasound Obstet Gynecol 2006; 27: 107113.
  • 11
    Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z. Nuchal translucency audit: a novel image scoring method. Ultrasound Obstet Gynecol 1998; 12: 398403.
  • 12
    Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343346.
  • 13
    Snijders RJ, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, Sabbagha RE, Filkins K, Silver RK, Hogge WA, Ginsberg NA, Beverley S, Morgan P, Blum K, Cilis P, Hill LM, Hecker J, Wapner RJ. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353359.
  • 14
    Dudley NJ, Chapman E. The importance of quality management in fetal measurement. Ultrasound Obstet Gynecol 2002; 19: 190196.
  • 15
    Salomon LJ, Bernard JP, Duyme M, Doris B, Mas N, Ville Y. Feasibility and reproducibility of an image-scoring method for quality control of fetal biometry in the second trimester. Ultrasound Obstet Gynecol 2006; 27: 3440.
  • 16
    Fries N, Althuser M, Fontanges M, Talmant C, Jouk PS, Tindel M, Duyme M. Quality control of an image-scoring method for nuchal translucency ultrasonography. Am J Obstet Gynecol 2007; 196: 272.e1272.e5.